Last Updated: 19/08/2025
Dissecting early Skin-based immune responses to PARasites in ControLled human infection studies to design novel vaccines (SPARCL)
Objectives
The EU funded SPARCL project will create a highly immunogenic, adjuvanted whole parasite vaccine. To assess its potency, it will measure early skin-based humoral and cellular immune markers. It will also review the functionality of antibodies by adapting molecular imaging tools. As a high-risk high-gain proposal, it will pave the way for a novel solution.
The unique preliminary data collected in the process indicated the role for the skin as a prime immunological organ and a preferred site of vaccination. Based on these findings, Prof Roestenberg proposes to create a next generation of highly effective vaccines, ready for pre-clinical testing. The research, if successful, may break the impasse in the field of parasite vaccines development and provide new tools and approaches in vaccinology.
May 2023 — Apr 2028
$1.65M
Related Resources
